Outcomes Similar for Therapy-Related, De Novo MDS After Haplo-HSCT
WEDNESDAY, Feb. 21, 2024 -- Patients with therapy-related myelodysplastic syndrome (t-MDS) and de novo MDS have comparable outcomes after haploidentical hematopoietic stem cell transplantation (haplo-HSCT), according to a study published online Feb.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 21, 2024 Category: Pharmaceuticals Source Type: news

All-Oral Therapy Promising in Higher-Risk MDS, CMML
(MedPage Today) -- An all-oral combination therapy appeared to show promising activity for patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML), with acceptable safety, according to results from a... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 5, 2024 Category: Hematology Source Type: news

Imetelstat Leads to Durable Red Blood Cell Transfusion Independence
TUESDAY, Jan. 9, 2024 -- For heavily transfused patients with lower-risk myelodysplastic syndromes (LR-MDS) who are not responding to or are ineligible for erythropoiesis-stimulating agents (ESAs), the competitive telomerase inhibitor imetelstat... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 9, 2024 Category: Pharmaceuticals Source Type: news

Peripheral Blood Haplo-SCT Feasible for Leukemia Patients 70 Years and Older
WEDNESDAY, Dec. 20, 2023 -- For patients with acute myeloid leukemia (AML)/myelodysplastic syndromes (MDS) aged 70 years and older, haploidentical stem cell transplantation (Haplo-SCT) using a nonmyeloablative conditioning regimen (NMAC) is... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 20, 2023 Category: Pharmaceuticals Source Type: news

Novel Therapy Reduced Transfusion Dependence in Lower-Risk MDS
(MedPage Today) -- Patients with lower-risk myelodysplastic syndromes (MDS) who relapsed or were refractory to standard treatment achieved improved rates of red blood cell (RBC) transfusion independence with an investigational, first-in-class telomerase... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 4, 2023 Category: Hematology Source Type: news

FDA OKs Ivosidenib for IDH1-mutated Myelodysplastic Syndromes FDA OKs Ivosidenib for IDH1-mutated Myelodysplastic Syndromes
The FDA approval was based on a small study, in which 38.9% of patients with relapsed or refractory disease went into complete remission.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 25, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Servier Announces FDA Approval of Tibsovo (ivosidenib tablets) for the Treatment of IDH1-Mutated Relapsed or Refractory (R/R) Myelodysplastic Syndromes (MDS)
Tibsovo is the first and only approved targeted therapy for R/R MDS patients with a susceptible IDH1 mutation Fifth approved indication for Tibsovo solidifies Servier ' s leadership in mutant IDH inhibition  BOSTON, Oct. 24, 2023 /PRNewswire/... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 24, 2023 Category: Drugs & Pharmacology Source Type: news

Tolerable Treatments Lacking for Higher-Risk Myelodysplastic Syndromes
FRIDAY, Oct. 20, 2023 -- There is a clear, unmet need for tolerable treatments that can produce durable remission among patients with higher-risk myelodysplastic syndromes (HR-MDS), according to a study published online Sept. 7 in Leukemia&... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 20, 2023 Category: Pharmaceuticals Source Type: news

Joanna Merlin, ‘Fiddler on the Roof’ Actress and Sondheim Casting Director, Dies at 92
Joanna Merlin, who created the role of the daughter Tzeitel in Fiddler on the Roof on Broadway and served as a casting director for Stephen Sondheim, Harold Prince and Bernardo Bertolucci, has died. She was 92. Merlin died Sunday in Los Angeles of complications from myelodysplastic syndrome, a…#joannamerlin #broadway #stephensondheim #haroldprince #bernardobertolucci #merlin #racheldretzin #juliedretzin #missberg #alanparkers (Source: Reuters: Health)
Source: Reuters: Health - October 17, 2023 Category: Consumer Health News Source Type: news

U.S. FDA Approves Bristol Myers Squibb ’s Reblozyl (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
PRINCETON, N.J.--(BUSINESS WIRE) August 28, 2023-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Reblozyl (luspatercept-aamt) for the treatment of anemia without previous... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 28, 2023 Category: Drugs & Pharmacology Source Type: news

Risks for MDS/Leukemia Increased for Survivors of Common Lymphoid Neoplasms
THURSDAY, Aug. 17, 2023 -- Survivors of common lymphoid neoplasms (LNs) have increased risks for therapy-related myelodysplastic syndrome/acute myeloid leukemia (tMDS/AML), although risks have been lower in more recent years, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 17, 2023 Category: Pharmaceuticals Source Type: news

Precursor to Blood Cancer Is'Tricky to Diagnose,' Study Shows
WEDNESDAY, Aug. 9, 2023 -- New research shows hard-to-diagnose blood disorders called myelodysplastic syndromes/neoplasms (MDS) are often misdiagnosed and a second opinion may be needed. The difficulty of diagnosis and frequent misdiagnosis puts... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 9, 2023 Category: General Medicine Source Type: news

International Prognostic Scoring System-Molecular Changes Clinical Management
FRIDAY, June 16, 2023 -- Implementing the International Prognostic Scoring System-Molecular (IPSS-M) in clinical practice could impact clinical management for nearly half of patients with myelodysplastic syndromes (MDS), according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 16, 2023 Category: Pharmaceuticals Source Type: news

Monoclonal Antibody Reduced Need For Transfusions in Low-Risk MDS
(MedPage Today) -- CHICAGO -- Patients with transfusion-dependent, low-risk myelodysplastic syndromes (MDS) needed significantly fewer transfusions when treated with luspatercept (Reblozyl) for anemia compared with the current standard of care... (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - May 25, 2023 Category: Urology & Nephrology Source Type: news

MRI-Based AI Can Distinguish Aplastic Anemia From MDS
MONDAY, April 24, 2023 -- A magnetic resonance imaging (MRI)-based machine learning method can distinguish aplastic anemia (AA) from myelodysplastic syndromes (MDS), according to a study published online March 6 in Clinical Radiology. P. Xiang,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 24, 2023 Category: Pharmaceuticals Source Type: news